Evolving Treatments of Metastatic CRC: Insights from ASCO 2024

The panel of CRC experts explores the significance of molecular testing for mCRC patients, emphasizing recommended biomarkers and optimal testing timelines.

Key opinion leaders outline their strategies for sequencing second-line treatments in chemotherapy-refractory metastatic colorectal cancer patients, considering the influence of previous therapies on their decision-making process.

The panel examines data from the ZL-IRIAN study and Phase II study, which provide insights into second-line treatment options for patients with metastatic colorectal cancer.

The panel examines prevalent adverse events experienced by patients receiving second-line biomarker-directed therapy for metastatic colorectal cancer.

The colorectal cancer experts offer insights on a patient case and investigate the obstacles faced by patients with metastatic colorectal cancer requiring third-line or later therapy.

Key opinion leaders explore treatment selection for third-line metastatic colorectal cancer patients, examining factors influencing therapy choice with particular focus on comparing fruquintinib to TAS-102 (with or without bevacizumab).

Leading colorectal cancer specialists analyze the SUNLIGHT trial results, focusing on age-related efficacy data and its implications for treatment strategies.

Oncology experts evaluate the influence of fruquintinib on current treatment protocols, drawing insights from the FRESCO and FRESCO-2 clinical studies.

Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.

The panel of leading oncologists summarize crucial updates and key insights on colorectal cancer from the ASCO 2024 conference.

Experts discuss their vision for the future of colorectal cancer treatment and anticipated advancements in the field.